Clinical Trial Update: The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis [Phase 3]

View source ↗

Summary

A Phase 3 study (AIRTIVITY) evaluating BI 1291583 for bronchiectasis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis

Drugs mentioned

• BI-1291583

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Bronchiectasis | Phase 3 | Status: RECRUITING